pirbuterol pirbuterol pirbuterol (trade name maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler. pirbuterolclinical datatrade namesmaxairahfs/drugs.comconsumer drug informationmedlineplusa601096pregnancycategory c routes ofadministrationinhalational (mdi)atc coder03ac08 (who) r03cc07 (who)legal statuslegal status au: s4 (prescription only) us: ℞-only identifiers iupac name (rs)-6--2-(hydroxymethyl)pyridin-3-ol cas number38677-81-5 yhcl: 38029-10-6 ypubchem cid4845iuphar/bps7272drugbankdb01291 ychemspider4679 yuniiog645j8rvwhcl: j6793t658k ykeggd08387 nchemblchembl1094966 ycomptox dashboard (epa)dtxsid0046937 chemical and physical dataformulac12h20n2o3molar mass240.303 g·mol−13d model (jsmol)interactive imagechiralityracemic mixture smiles oc1ccc(nc1co)c(o)cnc(c)(c)c inchi inchi=1s/c12h20n2o3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17h,6-7h2,1-3h3 ykey:vqdbnkdjnjqrdg-uhfffaoysa-n y ny (what is this?) (verify) it was patented in 1971 and came into medical use in 1983. medical use pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. it should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid. mode of action further information: beta2-adrenergic agonist pharmacokinetics after inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). a mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. pirbuterol is not metabolized by catechol-o-methyltransferase. the plasma half-life measured after oral administration is about two hours. adverse effects further information: beta2-adrenergic agonist